On Friday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened lower -22.73% from the last session, before settling in for the closing price of $12.32. Price fluctuations for NTLA have ranged from $5.90 to $28.25 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -20.04%. Company’s average yearly earnings per share was noted 22.63% at the time writing.
Intellia Therapeutics Inc (NTLA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.39%, while institutional ownership is 89.18%. The most recent insider transaction that took place on Oct 01 ’25, was worth 539. In this transaction EVP, Chief Scientific Officer of this company sold 31 shares at a rate of $17.38, taking the stock ownership to the 105,184 shares. Before that another transaction happened on Oct 01 ’25, when Company’s VP, Chief Accounting Officer sold 1,871 for $17.38, making the entire transaction worth $32,518. This insider now owns 55,266 shares in total.
Intellia Therapeutics Inc (NTLA) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -1.27 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -1.32) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.63% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.75% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 6.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.27, a number that is poised to hit -0.99 in the next quarter and is forecasted to reach -3.62 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Compared to the last year’s volume of 5.12 million, its volume of 11.07 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 12.08%.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 3.30%, which indicates a significant increase from 2.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.52 in the past 14 days, which was higher than the 1.11 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.19, while its 200-day Moving Average is $11.54. Nevertheless, the first resistance level for the watch stands at $10.10 in the near term. At $10.68, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.25. If the price goes on to break the first support level at $8.95, it is likely to go to the next support level at $8.38. Now, if the price goes above the second support level, the third support stands at $7.80.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 107,347K shares outstanding in the company with a market cap of 1.10 billion. Presently, the company’s annual sales total 57,880 K according to its annual income of -519,020 K. Last quarter, the company’s sales amounted to 14,250 K and its income totaled -101,260 K.
